Drugs / CAR gene-modified T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02664363 | Feb 2017 → Sep 2018 | gliosarcoma | Daniel Landi | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR gene-modified T cells | “The name of the drug is CAR gene-modified T cells or abbreviated as EGFRvIII CARs.” NCT02664363 ↗ |
| Modality | Cell therapy | “The drug substance is autologous T cells transduced with a retroviral vector encoding for a chimeric antigen receptor (CAR) directed against the tumor specific antigen, EGFRvIII.” NCT02664363 ↗ |
| Route | Intravenous | “the total dose of EGFRvIII CAR T cells were delivered intravenously.” NCT02664363 ↗ |